lichen planopilaris. Lichen planopilaris
Conditions
Interventions
Intervention 1: Intervention group: those who received 1 tablet of Pioglitazone 15 mg every day till the end of the experiment. Intervention 2: Control group: those who received topical Clobetasol lu
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: All patients between 15-70 years old with lichen planopilaris localized disease in which there was no need for systemic immunosuppressors no pregnancy or history of OCP consumption the patient a new case or was a known case who did not receive medication during the las three months no history of consuming a drug interaction with Pioglitazone no contraindication for Pioglitazone consumption such as diabetes mellitus, heart failure, hypersensitivity reaction to Pioglitazone Assign written informed consent
Exclusion criteria
Exclusion criteria: Unwillingness to participate pioglitazone contraindications (diabetes, heart failure, COPD, kidney or liver disease, diabetes, allergy to pioglitazone) pregnancy or OCP use progressive multifocal disease ( that is a candidate for systemic or immunosuppressive treatment) known case of LPP and a history of drug use in the past three months taking drugs interacting with pioglitazone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of lichen planopilaris based on lichen palonopilaris activity index. Timepoint: assessing the disease severity before starting the intervention and 2,4, 6 month after starting the medications. Method of measurement: Lichen planopilaris activity index. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Peymanfar
Tehran University of Medical Sciences
Outcome results
None listed